Table 3, Summary of the Sponsor’s Economic Evaluation Results for Satralizumab as Monotherapy Versus No Treatment - Pharmacoeconomic Report: Satralizumab (Enspryng)

Drug	Total costs ($)	Incremental costs ($)	Total QALYs	Incremental QALYs	ICER versus no treatment ($/QALY)
No treatment	827,346	Reference	1.99	Reference	Reference
Satralizumab	2,180,770	1,353,423	6.92	4.93	274,700

Cover of Pharmacoeconomic Report: Satralizumab (Enspryng)

Pharmacoeconomic Report: Satralizumab (Enspryng): (Hoffmann-La Roche Limited): Indication: Neuromyelitis optica spectrum disorder [Internet].

Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2021 Jun.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian Copyright Act and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

Except where otherwise noted, this work is distributed under the terms of a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International licence (CC BY-NC-ND), a copy of which is available at http://creativecommons.org/licenses/by-nc-nd/4.0/

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Table 3Summary of the Sponsor’s Economic Evaluation Results for Satralizumab as Monotherapy Versus No Treatment